RxDoctor Payments DataLook up a doctor →

Kurt Ashack, MD

Dermatology · Grand Rapids, MINPI 1073976338

Payments from drug & device makers

$206,913in general payments, 2019–2025

Across 487 payments — averaging $424.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$149K
  • Johnson & Johnson$23K
  • Sanofi$11K
  • Arcutis Biotherapeutics, Inc.$9K
  • Sanofi US Services Inc.$8K
  • UCB, Inc.$2K
  • plus $5K from 25 others

What the payments were for

  • Consulting fees$19,38610%
  • Speaking & faculty fees$160,86281%
  • Travel & lodging$7,5824%
  • Food & beverage$10,4235%
  • Education$6610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,913 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$220,442
Medicare patients
646
Services billed
3,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa44$871,845
Humira(Cf) PenAdalimumab30$310,529
StelaraUstekinumab14$251,451
Dupixent PenDupilumab25$113,444
Cosentyx Sensoready (2 Pens)Secukinumab13$94,367
Dupixent SyringeDupilumab14$54,842
Acitretin24$18,335
Fluorouracil206$12,401
Clobetasol Propionate330$8,875
Calcipotriene39$8,619
Metronidazole88$5,447
Tacrolimus51$4,082
Econazole Nitrate75$3,219
Betamethasone Dipropionate42$2,821
Tretinoin31$2,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$23,168$251,45114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.

Other dermatology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →